Details

Autor(en) / Beteiligte

• Courjon, Johan
• Senneville, Eric
• Illes, Hajnal-Gabriela
• Pavese, Patricia
• Boutoille, David
• Daoud, Frederic C.
• Dunkel, Nathalie
• Tattevin, Pierre

Titel

Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study

Ist Teil von

• International journal of antimicrobial agents, 2023-10, Vol.62 (4), p.106945-106945, Article 106945

Ort / Verlag

Elsevier Ltd

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •Dalbavancin was used mostly for off-label indications in France.•The effectiveness of dalbavancin in patients with a complete follow-up was 92.2%.•Dalbavancin-related adverse events were reported in 7.9% of patients.•Dalbavancin was used mostly in heavily pretreated patients in France. Dalbavancin is a lipoglycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections. However, several studies have suggested that it is used mostly for off-label indications. We aimed to describe the use of dalbavancin in patients who received at least one dose of the antibiotic in France. Prospective, observational, multicentre study conducted in France from September 2018 to April 2020. The primary outcome was the clinical response at 30 days after the last dalbavancin dose. A total of 151 patients in 16 centres were included in this study. The main infection sites were bone and joint infections (55.0%), multisite infections (15.9%), and vascular infections (14.6%), and the primary pathogens were coagulase-negative staphylococci (N = 82), Staphylococcus aureus (N = 51), and enterococci (N = 27). Most patients (71.5%) received three previous antibiotic treatments. The number of dalbavancin injections per patient was 1 in 26 patients (17.2%), 2 in 95 patients (62.9%), 3 in 17 patients (11.3%), and more than 3 in 13 patients (8.6%), with a mean cumulative dose of 3089 ± 1461 mg per patient. Among the 129 patients with a complete follow-up, clinical success was achieved in 119 patients (92.2%). At least 1 adverse event was reported in 67 patients (44.4%), including 12 (7.9%) patients with dalbavancin-related adverse events. The results of the study showed that dalbavancin is used mostly for off-label indications and in heavily pretreated patients in France. The clinical response at 30 days after the last dose was favourable in most patients, with a good safety profile.